[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-001", "question": "A 45-year-old man with autosomal dominant polycystic kidney disease presents with acute flank pain and hematuria. Imaging reveals a 6 cm cyst with internal septations and hemorrhage. Renal function is preserved, but he develops fever and leukocytosis. Blood cultures are negative, but cyst aspiration yields purulent fluid positive for Escherichia coli. Despite appropriate intravenous antibiotics, his symptoms persist. What is the most appropriate next step in management?", "options": ["Switch to a different antibiotic based on sensitivity testing", "Perform percutaneous cyst drainage and sclerotherapy", "Initiate long-term suppressive antibiotic therapy", "Surgical decortication of the infected cyst", "Administer intraparenchymal antibiotic infusion"], "answer": "D", "answer_index": 3, "explanation": "Surgical decortication is indicated for persistent cyst infection in polycystic kidney disease when antibiotics and drainage fail, as it allows complete removal of infected material. Percutaneous drainage often fails due to viscous cyst contents and multiloculation, while sclerotherapy is not appropriate for infected cysts. Long-term suppression or antibiotic switches do not address the source of ongoing infection.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: ADPKD with acute flank pain/hematuria, imaging shows 6 cm hemorrhagic cyst, fever/leukocytosis, E. coli from cyst aspiration, failure of appropriate IV antibiotics. The vignette describes a persistent infected cyst despite adequate antibiotics, making source control necessary. Surgical decortication (D) is the standard next step when percutaneous drainage is insufficient, aligning with guidelines for complex cyst infections. Alternatives are inferior: switching antibiotics (A) ignores source control; percutaneous drainage/sclerotherapy (B) often fails in multiloculated cysts; long-term suppression (C) is not definitive; intraparenchymal infusion (E) is not standard. No contradictions or missing details; the key matches the single best answer. Medical accuracy is sound. Minimal fix: None needed; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: ADPKD with acute flank pain/hematuria, imaging shows 6 cm hemorrhagic cyst, fever/leukocytosis, E. coli from cyst aspiration, failure of appropriate IV antibiotics. The vignette describes a persistent infected cyst despite adequate antibiotics, making source control necessary. Surgical decortication (D) is the standard next step when percutaneous drainage is insufficient, aligning with guidelines for complex cyst infections. Alternatives are inferior: switching antibiotics (A) ignores source control; percutaneous drainage/sclerotherapy (B) often fails in multiloculated cysts; long-term suppression (C) is not definitive; intraparenchymal infusion (E) is not standard. No contradictions or missing details; the key matches the single best answer. Medical accuracy is sound. Minimal fix: None needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-002", "question": "A 62-year-old woman with chronic lymphocytic leukemia develops petechiae and easy bruising. Laboratory studies show hemoglobin 9.2 g/dL, platelets 12,000/μL, and white blood cells 45,000/μL with 80% lymphocytes. Bone marrow biopsy reveals 90% infiltration by small lymphocytes. She has no active infection or bleeding. What is the most likely mechanism underlying her thrombocytopenia?", "options": ["Autoimmune destruction mediated by anti-platelet antibodies", "Bone marrow suppression from leukemic infiltration", "Hypersplenism with platelet sequestration", "Drug-induced thrombocytopenia from prior chemotherapy", "Microangiopathic hemolytic anemia with consumptive thrombocytopenia"], "answer": "B", "answer_index": 1, "explanation": "In advanced chronic lymphocytic leukemia, thrombocytopenia is primarily due to bone marrow infiltration by leukemic cells, crowding out normal hematopoiesis. Autoimmune thrombocytopenia occurs in only 1-2% of cases and typically responds to steroids, while hypersplenism is less common without massive splenomegaly. Drug effects or microangiopathy are not supported by the clinical scenario.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: advanced CLL with 90% marrow infiltration by lymphocytes, severe thrombocytopenia (12,000/μL), absence of active bleeding/infection, and no mention of splenomegaly or recent chemotherapy. Main logical issue: None; the vignette is internally consistent and points uniquely to marrow replacement. Main medical accuracy issue: None; the explanation aligns with standard hematology teaching that marrow infiltration is the most common cause of thrombocytopenia in advanced CLL. Minimal fix: No fix needed; the item is clear and accurate. Adding 'no splenomegaly' could further rule out hypersplenism, but it is already implied by the absence of relevant findings.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: advanced CLL with 90% marrow infiltration by lymphocytes, severe thrombocytopenia (12,000/μL), absence of active bleeding/infection, and no mention of splenomegaly or recent chemotherapy. Main logical issue: None; the vignette is internally consistent and points uniquely to marrow replacement. Main medical accuracy issue: None; the explanation aligns with standard hematology teaching that marrow infiltration is the most common cause of thrombocytopenia in advanced CLL. Minimal fix: No fix needed; the item is clear and accurate. Adding 'no splenomegaly' could further rule out hypersplenism, but it is already implied by the absence of relevant findings.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-003", "question": "A 28-year-old man with common variable immunodeficiency presents with recurrent sinopulmonary infections. Immunoglobulin levels show IgG 150 mg/dL, IgA <5 mg/dL, and IgM 20 mg/dL. He has absent responses to protein and polysaccharide vaccines. Genetic testing reveals a heterozygous mutation in the TACI gene. What is the most appropriate long-term management strategy?", "options": ["Monthly intravenous immunoglobulin replacement", "Prophylactic antibiotics with trimethoprim-sulfamethoxazole", "Hematopoietic stem cell transplantation", "Rituximab therapy to deplete B cells", "Interleukin-2 supplementation"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin replacement is the cornerstone of therapy for common variable immunodeficiency to prevent infections by providing passive immunity. Prophylactic antibiotics are adjunctive but not sufficient alone, while transplantation is reserved for severe cases with cellular defects. Rituximab and IL-2 are not standard for this humoral immunodeficiency.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Diagnosis of common variable immunodeficiency (CVID) with low IgG, low IgA, low IgM, absent vaccine responses, and a TACI mutation. This confirms a primary humoral immunodeficiency requiring antibody replacement. Main logical issue: None; the vignette is specific and supports a single best answer. Main medical accuracy issue: None; the keyed answer aligns with standard guidelines. Minimal fix: None required; the item is clear and accurate. The alternatives are correctly inferior: B (antibiotics) is adjunctive, C (transplant) is for severe cellular defects, D (rituximab) would worsen humoral immunity, and E (IL-2) is not indicated.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 826)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-004", "question": "A 35-year-old traveler returns from sub-Saharan Africa with fever, chills, and myalgias. Blood smear shows ring forms and gametocytes consistent with Plasmodium falciparum. He is treated with artemether-lumefantrine, but 48 hours later, parasitemia persists at 3%. Genotyping reveals a mutation in the PfKelch13 gene. What is the most appropriate next therapeutic intervention?", "options": ["Switch to atovaquone-proguanil", "Add primaquine for gametocytocidal effect", "Initiate intravenous artesunate", "Administer doxycycline as monotherapy", "Use mefloquine as alternative therapy"], "answer": "C", "answer_index": 2, "explanation": "Persistent parasitemia with PfKelch13 mutation indicates artemisinin resistance, necessitating intravenous artesunate for rapid parasite clearance in severe or resistant falciparum malaria. Atovaquone-proguanil or mefloquine may face cross-resistance, while primaquine and doxycycline are not first-line for acute treatment failure. Artesunate is recommended by WHO for such cases.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: traveler with falciparum malaria, persistent parasitemia after artemether-lumefantrine, PfKelch13 mutation (artemisinin resistance). This defines artemisinin-resistant malaria with treatment failure. Main logical issue: None; the stem uniquely points to severe/resistant infection requiring parenteral artesunate. Main medical accuracy issue: None; intravenous artesunate is WHO-recommended for artemisinin-resistant or severe malaria. Alternatives are inferior: A (atovaquone-proguanil) is oral and may have cross-resistance; B (primaquine) is for gametocyte clearance, not acute treatment; D (doxycycline monotherapy) is slow and adjunctive; E (mefloquine) may have resistance. Minimal fix: None needed; item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 921)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-005", "question": "A 55-year-old man with metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation progresses on osimertinib. Tumor biopsy shows transformation to small cell histology. He has good performance status. What is the most appropriate systemic therapy?", "options": ["Continue osimertinib with added chemotherapy", "Switch to amivantamab", "Initiate etoposide and platinum-based chemotherapy", "Use mobocertinib as targeted therapy", "Administer immune checkpoint inhibitor monotherapy"], "answer": "C", "answer_index": 2, "explanation": "Transformation to small cell lung cancer in EGFR-mutant NSCLC requires treatment as small cell carcinoma with etoposide-platinum chemotherapy, which has shown responses in such cases. Continuing EGFR inhibitors is ineffective post-transformation, while amivantamab and mobocertinib target specific exon 20 insertions but not small cell histology. Immunotherapy has limited efficacy in transformed disease.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: metastatic EGFR-mutant NSCLC with exon 20 insertion, progression on osimertinib, transformation to small cell histology, good performance status. The transformation to small cell lung cancer (SCLC) is the critical finding; standard of care for SCLC, regardless of prior oncogene-driven adenocarcinoma, is etoposide plus platinum-based chemotherapy. The item is logically valid: the stem uniquely points to SCLC-directed therapy, and option C is the only choice matching that. Alternatives are incorrect: continuing or switching EGFR-targeted therapies (A, B, D) is ineffective post-transformation, and immunotherapy monotherapy (E) is not first-line for SCLC. Medical accuracy is sound, aligning with guidelines. Minimal fix: None required; the item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 960)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-006", "question": "A 12-year-old boy with hereditary angioedema type I presents with recurrent abdominal pain and facial swelling. Laboratory studies show C1 inhibitor level 20% of normal and low C4. He has breakthrough episodes despite prophylactic danazol. What is the most appropriate escalation in therapy?", "options": ["Switch to tranexamic acid prophylaxis", "Initiate subcutaneous C1 inhibitor replacement", "Add icatibant for on-demand treatment", "Use ecallantide for acute attacks", "Administer fresh frozen plasma infusions"], "answer": "B", "answer_index": 1, "explanation": "Subcutaneous C1 inhibitor replacement is effective for prophylaxis in hereditary angioedema with breakthrough on androgens, providing targeted replacement of the deficient protein. Tranexamic acid is less effective for type I, while icatibant and ecallantide are for acute treatment, not prophylaxis. Fresh frozen plasma carries risks and is not preferred for long-term use.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: hereditary angioedema type I, breakthrough episodes on danazol prophylaxis, question asks for 'most appropriate escalation in therapy' implying a new prophylactic strategy. The keyed answer (B) correctly identifies subcutaneous C1 inhibitor replacement as the guideline-recommended next-line prophylactic option when androgen therapy fails. Alternatives A, C, D, and E are inferior: tranexamic acid is less effective for type I; icatibant and ecallantide are for acute on-demand treatment, not prophylaxis; fresh frozen plasma is not a standard long-term prophylactic option. No logical contradictions or underspecification. Medical accuracy is sound. Minimal fix: none required; item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 879)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-007", "question": "An 82-year-old woman with mild cognitive impairment presents with recurrent falls and orthostatic hypotension. She takes donepezil 10 mg daily. Autonomic testing shows sympathetic denervation. Brain MRI reveals hippocampal atrophy. What is the most likely underlying diagnosis contributing to her symptoms?", "options": ["Alzheimer disease with autonomic involvement", "Lewy body dementia", "Multiple system atrophy", "Vascular parkinsonism", "Progressive supranuclear palsy"], "answer": "B", "answer_index": 1, "explanation": "Lewy body dementia often presents with orthostatic hypotension due to autonomic dysfunction, recurrent falls, and cognitive impairment with hippocampal atrophy on MRI. Alzheimer disease rarely causes significant autonomic symptoms, while multiple system atrophy typically has more severe parkinsonism and cerebellar signs. Vascular parkinsonism and PSP lack prominent autonomic features.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: recurrent falls, orthostatic hypotension, mild cognitive impairment, sympathetic denervation on autonomic testing, hippocampal atrophy on MRI. The vignette describes a patient with mild cognitive impairment, recurrent falls, orthostatic hypotension, and autonomic testing showing sympathetic denervation. While Lewy body dementia (B) is a plausible cause, multiple system atrophy (C) is a more definitive and classic cause of pure autonomic failure with sympathetic denervation, especially in the context of recurrent falls and orthostatic hypotension, and is often a key differential. The hippocampal atrophy is non-specific. This creates a scenario where option C is equally or more defensible based on the autonomic findings, making B not uniquely best. Main logical issue: The keyed answer is not the single best answer; the stem's emphasis on autonomic failure makes MSA a strong contender. Main medical accuracy issue: The rationale incorrectly states Alzheimer disease 'rarely' causes autonomic symptoms; it can have autonomic involvement, though less prominent. Minimal fix: Add a finding more specific to Lewy body dementia (e.g., visual hallucinations or REM sleep behavior disorder) to distinguish it from MSA.\",\n    \"medical_accuracy_score\":  \"3\",\n    \"logical_validity\": false,\n    \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: recurrent falls, orthostatic hypotension, mild cognitive impairment, sympathetic denervation on autonomic testing, hippocampal atrophy on MRI. The vignette describes a patient with mild cognitive impairment, recurrent falls, orthostatic hypotension, and autonomic testing showing sympathetic denervation. While Lewy body dementia (B) is a plausible cause, multiple system atrophy (C) is a more definitive and classic cause of pure autonomic failure with sympathetic denervation, especially in the context of recurrent falls and orthostatic hypotension, and is often a key differential. The hippocampal atrophy is non-specific. This creates a scenario where option C is equally or more defensible based on the autonomic findings, making B not uniquely best. Main logical issue: The keyed answer is not the single best answer; the stem's emphasis on autonomic failure makes MSA a strong contender. Main medical accuracy issue: The rationale incorrectly states Alzheimer disease 'rarely' causes autonomic symptoms; it can have autonomic involvement, though less prominent. Minimal fix: Add a finding more specific to Lewy body dementia (e.g., visual hallucinations or REM sleep behavior disorder) to distinguish it from MSA.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-008", "question": "A 58-year-old man with IgA nephropathy and chronic kidney disease stage 4 develops hyperkalemia refractory to dietary restriction and loop diuretics. Serum potassium is 6.8 mEq/L with normal acid-base status. He is not on ACE inhibitors. What is the most appropriate pharmacologic intervention?", "options": ["Initiate sodium polystyrene sulfonate", "Start patiromer therapy", "Administer sodium zirconium cyclosilicate", "Use fludrocortisone acetate", "Prescribe sodium bicarbonate supplementation"], "answer": "D", "answer_index": 3, "explanation": "Fludrocortisone promotes potassium excretion in the distal tubule and is useful for hyperkalemia in hypoaldosteronism-like states in CKD without acidosis. Patiromer and zirconium are binders for chronic management but less effective in advanced CKD without dialysis. Polystyrene sulfonate has safety concerns, and bicarbonate is for acidotic states.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: advanced CKD (stage 4), refractory hyperkalemia (K+ 6.8 mEq/L), normal acid-base status, not on ACEi. The most appropriate immediate pharmacologic intervention for severe, refractory hyperkalemia is stabilization of cardiac membranes with IV calcium and shifting potassium intracellularly (e.g., insulin/glucose, albuterol), none of which are listed. Among the listed chronic management options for hyperkalemia, potassium-binding agents (patiromer, sodium zirconium cyclosilicate) are guideline-recommended first-line for chronic management in CKD. Fludrocortisone (keyed answer) is not a first-line agent due to risks of fluid overload and hypertension, especially in advanced CKD, making it a poor and potentially harmful best answer. The item is miskeyed. Minimal fix: Change the key to B or C (a binder) and adjust the rationale, or, more appropriately, add acute management options (e.g., IV calcium gluconate) to the list and re-key.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: advanced CKD (stage 4), refractory hyperkalemia (K+ 6.8 mEq/L), normal acid-base status, not on ACEi. The most appropriate immediate pharmacologic intervention for severe, refractory hyperkalemia is stabilization of cardiac membranes with IV calcium and shifting potassium intracellularly (e.g., insulin/glucose, albuterol), none of which are listed. Among the listed chronic management options for hyperkalemia, potassium-binding agents (patiromer, sodium zirconium cyclosilicate) are guideline-recommended first-line for chronic management in CKD. Fludrocortisone (keyed answer) is not a first-line agent due to risks of fluid overload and hypertension, especially in advanced CKD, making it a poor and potentially harmful best answer. The item is miskeyed. Minimal fix: Change the key to B or C (a binder) and adjust the rationale, or, more appropriately, add acute management options (e.g., IV calcium gluconate) to the list and re-key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-009", "question": "A 40-year-old woman with sickle cell disease presents with acute chest syndrome. She has hypoxia, fever, and new infiltrates on chest X-ray. Hemoglobin is 6.5 g/dL, reticulocytes 12%. Transfusion is initiated, but she develops worsening dyspnea and hypertension. What is the most likely complication?", "options": ["Transfusion-related acute lung injury", "Hyperhemolysis syndrome", "Transfusion-associated circulatory overload", "Delayed hemolytic transfusion reaction", "Acute hemolytic reaction from alloantibodies"], "answer": "C", "answer_index": 2, "explanation": "Transfusion-associated circulatory overload is common in sickle cell patients with acute chest syndrome due to volume sensitivity and underlying cardiac strain, presenting with hypertension and dyspnea. TRALI typically involves hypotension, while hyperhemolysis shows hemolysis without volume overload. Delayed reactions occur later, and acute hemolysis presents with fever and back pain.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: sickle cell disease, acute chest syndrome, hypoxia, fever, infiltrates, anemia with reticulocytosis, transfusion initiated, then worsening dyspnea and hypertension. The most likely complication is Transfusion-related acute lung injury (TRALI), which presents with acute hypoxemia and pulmonary edema within 6 hours of transfusion, often with hypertension initially, and is a leading cause of transfusion-related mortality. The keyed answer (C, TACO) is less likely as TACO typically presents with clear volume overload signs (e.g., elevated JVP, peripheral edema) not mentioned, and hypertension alone is not specific. The item's logic incorrectly dismisses TRALI based on 'typically involves hypotension,' which is not absolute; hypertension can occur. Main medical issue: oversimplified TRALI presentation. Minimal fix: Change key to A (TRALI) and adjust rationale to acknowledge hypertension can be present.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: sickle cell disease, acute chest syndrome, hypoxia, fever, infiltrates, anemia with reticulocytosis, transfusion initiated, then worsening dyspnea and hypertension. The most likely complication is Transfusion-related acute lung injury (TRALI), which presents with acute hypoxemia and pulmonary edema within 6 hours of transfusion, often with hypertension initially, and is a leading cause of transfusion-related mortality. The keyed answer (C, TACO) is less likely as TACO typically presents with clear volume overload signs (e.g., elevated JVP, peripheral edema) not mentioned, and hypertension alone is not specific. The item's logic incorrectly dismisses TRALI based on 'typically involves hypotension,' which is not absolute; hypertension can occur. Main medical issue: oversimplified TRALI presentation. Minimal fix: Change key to A (TRALI) and adjust rationale to acknowledge hypertension can be present.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-010", "question": "A 50-year-old man with rheumatoid arthritis on methotrexate develops pancytopenia. Bone marrow biopsy shows hypocellularity with absent megakaryocytes. Autoantibody testing is negative. Genetic analysis reveals shortened telomeres and a TERT mutation. What is the most appropriate definitive treatment?", "options": ["Switch to alternative immunosuppressive therapy", "Initiate danazol for telomere elongation", "Perform allogeneic hematopoietic stem cell transplant", "Administer eltrombopag as thrombopoietin mimetic", "Use anti-thymocyte globulin with cyclosporine"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic stem cell transplant is curative for dyskeratosis congenita-related aplastic anemia due to telomere biology disorders, addressing the underlying genetic defect. Danazol may stabilize telomeres temporarily but is not definitive, while immunosuppressives like ATG are for acquired aplasia. Eltrombopag stimulates residual marrow but does not correct the genetic issue.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: Pancytopenia, hypocellular marrow, absent megakaryocytes, negative autoantibodies, shortened telomeres, and a TERT mutation. This constellation is diagnostic of a telomere biology disorder (e.g., dyskeratosis congenita) causing aplastic anemia. The logical issue is miskeying. While allogeneic hematopoietic stem cell transplant (HSCT) is a definitive, curative treatment for severe aplastic anemia in this context, the stem does not specify disease severity, age, donor availability, or fitness for transplant—all critical for deeming HSCT the \\\"most appropriate definitive treatment\\\" at this point. The item's keyed answer (C) is a major intervention, but initial management for a newly diagnosed, stable patient would involve confirming the diagnosis and assessing eligibility, making danazol (B) a plausible first-line definitive medical therapy to address the telomere defect. This creates a defensible alternative, leading to a miskey. Medical accuracy is sound. Minimal fix: Change the stem to specify 'severe aplastic anemia' or 'refractory to medical therapy' to uniquely justify HSCT as the next definitive step.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1308)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-011", "question": "A 25-year-old man with HIV on antiretroviral therapy presents with headache and seizures. CSF analysis shows lymphocytic pleocytosis, elevated protein, and positive India ink stain. MRI reveals multiple ring-enhancing lesions. CD4 count is 150 cells/μL. What is the most appropriate initial management?", "options": ["Start amphotericin B and flucytosine induction", "Initiate pyrimethamine and sulfadiazine", "Administer acyclovir for herpes encephalitis", "Use intravenous ceftriaxone for bacterial meningitis", "Prescribe albendazole for neurocysticercosis"], "answer": "A", "answer_index": 0, "explanation": "Cryptococcal meningitis in HIV presents with India ink-positive CSF and ring-enhancing lesions, requiring induction with amphotericin B and flucytosine for clearance. Toxoplasmosis lacks India ink positivity, while herpes, bacterial, and parasitic etiologies do not match the CSF findings. Prompt antifungal therapy reduces mortality in this setting.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: HIV with CD4 150, headache/seizures, CSF lymphocytic pleocytosis/elevated protein/positive India ink stain, MRI ring-enhancing lesions. These findings are classic for cryptococcal meningitis in advanced HIV. The keyed answer (amphotericin B + flucytosine) is the standard induction therapy. Alternatives are incorrect: pyrimethamine/sulfadiazine is for toxoplasmosis (India ink negative), acyclovir for HSV encephalitis (different CSF), ceftriaxone for bacterial meningitis (typically neutrophilic pleocytosis), albendazole for neurocysticercosis (no India ink). No logical contradictions or missing details. Medical accuracy is sound. Minimal fix: None required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: HIV with CD4 150, headache/seizures, CSF lymphocytic pleocytosis/elevated protein/positive India ink stain, MRI ring-enhancing lesions. These findings are classic for cryptococcal meningitis in advanced HIV. The keyed answer (amphotericin B + flucytosine) is the standard induction therapy. Alternatives are incorrect: pyrimethamine/sulfadiazine is for toxoplasmosis (India ink negative), acyclovir for HSV encephalitis (different CSF), ceftriaxone for bacterial meningitis (typically neutrophilic pleocytosis), albendazole for neurocysticercosis (no India ink). No logical contradictions or missing details. Medical accuracy is sound. Minimal fix: None required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-012", "question": "A 65-year-old woman with triple-negative breast cancer metastatic to liver and bones receives paclitaxel. After the third cycle, she develops grade 3 neuropathy and pancytopenia. Germline testing reveals a PALB2 mutation. What is the most appropriate adjustment to her treatment regimen?", "options": ["Switch to eribulin monotherapy", "Add olaparib as PARP inhibitor", "Initiate sacituzumab govitecan", "Use capecitabine as oral chemotherapy", "Administer talazoparib with dose reduction"], "answer": "B", "answer_index": 1, "explanation": "PALB2 mutations confer sensitivity to PARP inhibitors like olaparib in metastatic breast cancer, offering a targeted approach after chemotherapy toxicity. Eribulin and capecitabine are chemotherapies without targeting the mutation, while sacituzumab is for later lines. Talazoparib is another PARP but not first-choice here.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: triple-negative breast cancer metastatic to liver/bones, developed grade 3 neuropathy and pancytopenia on paclitaxel, germline PALB2 mutation. The question asks for the most appropriate adjustment to her treatment regimen. The keyed answer (B, olaparib) is a targeted therapy for PALB2 mutation, but the stem's critical detail is the patient's active, severe (grade 3) toxicity from chemotherapy, which necessitates a change primarily due to tolerability, not just mutation status. This creates a logical conflict: the best adjustment must address toxicity, and simply adding a PARP inhibitor (olaparib) does not mitigate the existing neuropathy/pancytopenia from paclitaxel. Option E (talazoparib with dose reduction) is a PARP inhibitor that also addresses toxicity via dose reduction, making it a more defensible best answer for an 'adjustment' in this context, though the stem is underspecified (U) regarding whether to continue, hold, or switch paclitaxel. Main medical accuracy issue: While PARP inhibitors are indicated for PALB2-mutated metastatic breast cancer, ignoring active high-grade toxicity in favor of adding a drug is clinically unrealistic. Minimal fix: Clarify the intent by stating 'paclitaxel is held due to toxicity' to make adding a PARP inhibitor (B) the unambiguous best step, or specify 'requires a new regimen due to intolerance' to make switching to a PARP inhibitor with dose management (E) the clear choice.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: triple-negative breast cancer metastatic to liver/bones, developed grade 3 neuropathy and pancytopenia on paclitaxel, germline PALB2 mutation. The question asks for the most appropriate adjustment to her treatment regimen. The keyed answer (B, olaparib) is a targeted therapy for PALB2 mutation, but the stem's critical detail is the patient's active, severe (grade 3) toxicity from chemotherapy, which necessitates a change primarily due to tolerability, not just mutation status. This creates a logical conflict: the best adjustment must address toxicity, and simply adding a PARP inhibitor (olaparib) does not mitigate the existing neuropathy/pancytopenia from paclitaxel. Option E (talazoparib with dose reduction) is a PARP inhibitor that also addresses toxicity via dose reduction, making it a more defensible best answer for an 'adjustment' in this context, though the stem is underspecified (U) regarding whether to continue, hold, or switch paclitaxel. Main medical accuracy issue: While PARP inhibitors are indicated for PALB2-mutated metastatic breast cancer, ignoring active high-grade toxicity in favor of adding a drug is clinically unrealistic. Minimal fix: Clarify the intent by stating 'paclitaxel is held due to toxicity' to make adding a PARP inhibitor (B) the unambiguous best step, or specify 'requires a new regimen due to intolerance' to make switching to a PARP inhibitor with dose management (E) the clear choice.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-013", "question": "A 4-year-old girl with Wiskott-Aldrich syndrome presents with eczema, thrombocytopenia, and recurrent infections. She has low IgM and elevated IgE. Hematopoietic stem cell transplant is planned, but she develops hives after platelet transfusion. What is the most likely immunologic mechanism?", "options": ["IgA deficiency leading to anti-IgA antibodies", "Type I hypersensitivity to platelet antigens", "Complement activation by immune complexes", "IgE-mediated reaction to plasma proteins", "Delayed T-cell mediated hypersensitivity"], "answer": "D", "answer_index": 3, "explanation": "Elevated IgE in Wiskott-Aldrich syndrome predisposes to allergic reactions, including IgE-mediated hives from plasma proteins in transfusions. IgA deficiency is not typical, while type I hypersensitivity to antigens is less specific. Complement or T-cell mechanisms do not explain acute urticaria.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Wiskott-Aldrich syndrome (WAS) with eczema, thrombocytopenia, low IgM, elevated IgE; hives after platelet transfusion. The most likely immunologic mechanism for acute urticaria post-transfusion is IgE-mediated hypersensitivity. However, the keyed answer (D) specifies 'IgE-mediated reaction to plasma proteins,' which is overly specific and not the best-supported mechanism. The more precise and defensible best answer is B: Type I hypersensitivity to platelet antigens, as platelet concentrates contain plasma proteins and platelet-specific antigens, and IgE-mediated urticarial reactions are a recognized complication. Option D is a subset of B but incorrectly limits the trigger. No internal contradiction or underspecification exists. Medical accuracy is sound. Minimal fix: Change key from D to B, or rephrase D to 'IgE-mediated hypersensitivity reaction to transfused components.'\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1066)"}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-014", "question": "A 78-year-old man with frailty and multimorbidity is admitted for pneumonia. He has a history of recurrent Clostridium difficile infections. Stool testing is positive for toxin. He completed vancomycin taper 2 weeks ago. What is the most appropriate treatment considering his geriatric status?", "options": ["Repeat oral vancomycin course", "Initiate fidaxomicin therapy", "Administer bezlotoxumab infusion", "Perform fecal microbiota transplant", "Use metronidazole as alternative"], "answer": "C", "answer_index": 2, "explanation": "Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, reduces recurrence in high-risk elderly patients without altering gut flora, ideal for frail geriatrics. Fidaxomicin is effective but costly, while repeat vancomycin increases resistance risk. Transplant is invasive, and metronidazole is inferior for recurrences.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: elderly frail patient with recurrent C. difficile infection (CDI) who just completed a vancomycin taper 2 weeks ago and is now toxin-positive again. This defines a recurrent CDI. The most appropriate treatment for recurrent CDI, especially in a frail patient with a history of recurrence, is fidaxomicin (option B) or fecal microbiota transplant (FMT, option D), as per major guidelines (IDSA/SHEA). Bezlotoxumab (keyed answer C) is an adjunct to antibiotic therapy to *prevent* recurrence, not a primary treatment for an active infection. The stem does not indicate it is being given with an antibiotic. Thus, a unique best answer exists (fidaxomicin is guideline-preferred over repeat vancomycin for recurrence), but the provided key (bezlotoxumab) is not it. Main medical issue: bezlotoxumab is misapplied as monotherapy. Minimal fix: Change the key to B (fidaxomicin) or, to make C correct, rephrase the stem to ask for an adjunct to prevent *future* recurrence after completing a current antibiotic course.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: elderly frail patient with recurrent C. difficile infection (CDI) who just completed a vancomycin taper 2 weeks ago and is now toxin-positive again. This defines a recurrent CDI. The most appropriate treatment for recurrent CDI, especially in a frail patient with a history of recurrence, is fidaxomicin (option B) or fecal microbiota transplant (FMT, option D), as per major guidelines (IDSA/SHEA). Bezlotoxumab (keyed answer C) is an adjunct to antibiotic therapy to *prevent* recurrence, not a primary treatment for an active infection. The stem does not indicate it is being given with an antibiotic. Thus, a unique best answer exists (fidaxomicin is guideline-preferred over repeat vancomycin for recurrence), but the provided key (bezlotoxumab) is not it. Main medical issue: bezlotoxumab is misapplied as monotherapy. Minimal fix: Change the key to B (fidaxomicin) or, to make C correct, rephrase the stem to ask for an adjunct to prevent *future* recurrence after completing a current antibiotic course.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]